Format

Send to

Choose Destination
Bone Marrow Transplant. 2014 Jun;49(6):744-50. doi: 10.1038/bmt.2014.55. Epub 2014 Mar 17.

Hematopoietic SCT in Europe: data and trends in 2012 with special consideration of pediatric transplantation.

Author information

1
EBMT Activity Survey Office, Division of Hematology, Department of Medicine, University Hospital, Basel, Switzerland.
2
BMT Unit, St Anna Kinderspital, Vienna, Austria.
3
Molecular Immunology Unit, UCL Institute of Child Health, London, UK.
4
Paediatric HaematologyOncology, Policlinico G.B. Rossi, Verona, Italy.
5
University of Heidelberg, Medizinische Klinik u. Poliklinik V, Heidelberg, Germany.
6
Institut Catalàd'Oncologia, Hospital Duran i Reynals, Barcelona, Spain.
7
Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands.
8
Service de Médecine Interne, Hopital St Louis, Paris, France.
9
Children's BMT Unit, Great North Children's Hospital, Royal Victoria Infirmary, Newcastle-Upon-Tyne, UK.
10
JACIE Accreditation Committee, Basel, Switzerland.
11
University Hospital Eppendorf, Hamburg, Germany.
12
St Anna Hospital, Ferrare, Italy.
13
Department of Haematological Medicine, GKT School of Medicine, London, UK.
14
INSERM UMRs 938, Universite Pierre & Maris Curie, Hôpital Saint Antoine, Paris, France.
15
Department of Haematology, Addenbrookes Hospital, Cambridge, UK.
16
Ospedale Santa Maria della Misericordia - Sezione di Ematologia, LocalitáSant Andrea delle Fratte, Perugia, Italy.
17
Anthony Nolan Research Institute, Royal Free Hospital, London, UK.

Abstract

In all, 661 of 680 centers in 48 countries reported 37 818 hematopoietic SCT (HSCT) in 33 678 patients (14 165 allogeneic (42%), 19 513 autologous (58%)) in the 2012 survey. Main indications were leukemias, 10 641 (32%; 95% allogeneic); lymphoid neoplasias, 19 336 (57%; 11% allogeneic); solid tumors, 1630 (5%; 3% allogeneic); and nonmalignant disorders, 1953 (6%; 90% allogeneic). There were more unrelated donors than HLA-identical sibling donors (54% versus 38% (8% being mismatched related donor HSCT)). Cord blood was almost exclusive in allogeneic transplants (5% of total). Since 2011, the highest increases in allogeneic HSCT were for AML in CR1 (12%) and for myeloproliferative neoplasm (15%). For autologous HSCT the main increases were for plasma cell disorders (7%), non-Hodgkin lymphoma (4%) and autoimmune disease (50%). There were 4097 pediatric patients <18 years of age receiving HSCT, 2902 received an allogeneic and 1195 an autologous HSCT. Overall, 69% of allogeneic and 64% of autologous HSCT were performed in dedicated pediatric centers and the remainder in combined adult and pediatric centers. Distributions of diseases, donor types and stem cell source for all patients and pediatric patients in particular are shown. A percentage of centers fulfilling the annual required criteria for patient numbers for JACIE accreditation are provided.

PMID:
24637898
PMCID:
PMC4051369
DOI:
10.1038/bmt.2014.55
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center